The Antidiabetic Agent Acarbose Improves Anti-PD-1 and Rapamycin Efficacy in Preclinical Renal Cancer

The Antidiabetic Agent Acarbose Improves Anti-PD-1 and Rapamycin Efficacy in Preclinical Renal Cancer

Although immune checkpoint inhibitors and targeted therapeutics have changed the landscape of treatment for renal cell carcinoma (RCC), most patients do not experience significant clinical benefits. Emerging preclinical studies report that nutrition-based interventions and glucose-regulating agents...

Full description

Bibliographic Details
Main Authors: Rachael M. Orlandella, William J. Turbitt, Justin T. Gibson, Shannon K. Boi, Peng Li, Daniel L. Smith, Lyse A. Norian
Format: Article
Language:English
Published: MDPI AG 2020-10-01
Series:Cancers
Subjects:
kidney cancer
glucose
immunity
nutrition
immunotherapy
Online Access:https://www.mdpi.com/2072-6694/12/10/2872

Similar Items

Similar Items